CON

• The company purchased 1,000,000 shares of common stock at $34.65 per share, totaling $34,650,000, a 1% discount to the August 21, 2026 closing price.
• The transaction closed on August 24, 2026 and was funded with cash on hand.
• The repurchased shares represent approximately 0.784% of the company's outstanding common stock immediately prior to the transaction.
• The purchase was approved by the Audit and Compliance Committee and made under the company's previously announced share repurchase program.

1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits

• Keith Newton will resign as CEO and transition to Executive Chairman, effective November 1, 2026.
• Matt DiCanio, currently President and CFO, will become President and CEO and a Class III director, effective November 1, 2026.
• No compensation determinations have been made for DiCanio's promotion as of the filing date.
• The company expects to announce its CFO succession plan before the leadership transition takes effect.

2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits

• Dr. John R. Anderson will retire as Executive Vice President and Chief Medical Officer effective December 31, 2026.
• Dr. Anderson will provide up to 10 hours per week of consulting services at $216.00 per hour.
• His unvested restricted stock awards will continue to vest during the consulting term, with 25% of then-unvested shares vesting if he completes the full term.
• The consulting agreement may be terminated by either party with 30 days' notice, or immediately by Concentra for cause.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits

• Net income was $52.3 million, up 28.7% from $40.6 million in Q1 2025.
• Adjusted EBITDA was $120.7 million, up 17.6% from $102.7 million in Q1 2025.
• The company raised FY 2026 guidance: revenue of $2.275B-$2.375B and Adjusted EBITDA of $460M-$480M.
• Board declared a cash dividend of $0.0625 per share, payable June 9, 2026.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits

• Concentra Group Holdings Parent, Inc. held its annual meeting of stockholders on April 30, 2026.
• The non-binding advisory vote on named executive officer compensation was approved with 114,180,227 votes for and 5,143,479 against.
• Stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
• The report was filed under Item 5.07 to disclose the final voting results of the matters submitted to a stockholder vote.

5.07 Submission of Matters to a Vote of Security Holders

• Dr. John Anderson notified Concentra of his retirement as Executive Vice President and Chief Medical Officer, effective December 31, 2026.
• Concentra has initiated a formal search for Dr. Anderson's successor.
• Dr. Anderson joined Concentra in 1993 and has served as Chief Medical Officer since 2014.
• A press release announcing the retirement was issued on April 14, 2026.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Q4 2025 net income was $36.2 million, up 58.7% from $22.8 million in Q4 2024.
• Full year 2025 revenue was $2,163.4 million, up 13.9% from $1,900.2 million in 2024.
• Full year 2025 net income was $172.8 million, slightly up from $171.9 million in 2024.
• For 2026, the company expects revenue of $2.25-$2.35 billion and Adjusted EBITDA of $450-$470 million.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits

• Full year 2025 revenue expected at $2,163.4 million, up 13.9% from $1,900.2 million in FY 2024.
• Q4 2025 Adjusted EBITDA expected at $95.3 million, up 22.9% from $77.5 million in Q4 2024; FY 2025 Adjusted EBITDA expected at $431.9 million, up 14.6% from $376.9 million in FY 2024.
• FY 2026 guidance: revenue $2.25B-$2.35B, Adjusted EBITDA $450M-$470M, free cash flow $200M-$225M, capex $70M-$80M, net leverage 3.0x or below.
• Full Q4 and FY 2025 results to be released on February 26, 2026, with a conference call on February 27, 2026.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits